Previous 10 | Next 10 |
home / stock / sabsw / sabsw news
SIOUX FALLS, S.D., Aug. 09, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics ( Nasdaq: SABS ), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully human polyclonal antibodies without the need for ...
SIOUX FALLS, S.D., Aug. 04, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (NASDAQ: SABS), a clinical-stage biopharmaceutical company with a first of its kind immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human...
SIOUX FALLS, S.D., July 11, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully human polyclonal antibodies without the need for human dono...
SIOUX FALLS, S.D., July 05, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB, or “the Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully human polyclonal antibodies...
SIOUX FALLS, S.D., June 06, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics ( Nasdaq: SABS ), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully human polyclonal antibodies without the need for ...
In-person presentation titled ‘Leveraging Genetically Engineered Ungulates to Produce Novel Human Biotherapeutics’ to take place on June 7 in Park City, Utah Dr. Christoph Bausch to share early R&D updates on SAB novel platform advancement toward developing Tra...
Full data from Phase 2a trial that evaluated SAB-176 for treatment of seasonal influenza expected third quarter 2022 – first clinical data set from novel platform Phase 2 data for SAB-185 expected to be available later this year Sufficient cash anticipated to oper...
SIOUX FALLS, S.D., May 12, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (NASDAQ: SABS), announced today its participation at the H.C. Wainwright Global Investment Conference , which takes place May 23-26, 2022. As part of the conference, the company’s management team will partici...
SIOUX FALLS, S.D., April 05, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics ( Nasdaq: SABS ), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for...
SAB executing on its strategy to build a proprietary immune and autoimmune disorders pipeline, including respiratory diseases that affect immunocompromised patients Plans to announce full data from Phase 2a trial that evaluated SAB-176 for the treatment of seasonal inf...
News, Short Squeeze, Breakout and More Instantly...
SAB Biotherapeutics Inc. Warrant Company Name:
SABSW Stock Symbol:
NASDAQ Market:
SAB Biotherapeutics Inc. Warrant Website:
New name, logo and website updates, stock symbol will remain SABS With new brand identity, SAB BIO continues drive towards serious unmet needs in type 1 diabetes MIAMI, June 20, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the “Company” or “SAB...
MIAMI, June 18, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progre...
MIAMI, May 30, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progres...